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prevalence, cervical lesions, and genital warts in adolescent girls in
the years since the introduction of the ﬁrst HPV vaccine in 2006
(Markowitz et al., 2014; Hariri et al., 2015; Smith et al., 2015). In addi-
tion, HPV vaccines have been found to be quite safe: clinical trials and
numerous post-licensure safety studies have found no consistent evi-
dence of causal association of HPV vaccination with prespeciﬁed health
conditions includingGuillain–Barré syndrome, stroke, venous thrombo-
embolism, appendicitis, seizures, allergic reactions, anaphylaxis, auto-
immune disorders, or a variety of neurologic conditions (Markowitz
et al., 2014). However, a number of countries have received, and contin-
ue to receive, reports alleging the association of HPV vaccination with a
variety of adverse health events, many of which have been systemati-
cally investigated and no causal relationships found (Wilson et al.,
2015). Reports have engendered a spectrum of immunization program
responses (Wilson et al., 2015). In 2013, subsequent to a concern about
Complex Regional Pain Syndrome (CRPS) after receipt of HPV 16/18
vaccine, Japan temporarily suspended the national HPV vaccination
recommendation. In this issue of EBioMedicine, the risk of CRPS after
receipt of HPV 16/18 vaccine is explored in a study by Huygen et al.
(2015).
CRPS is a condition of chronic, severe, often burning pain, usually in
oneormore extremities, that is often accompanied by swelling, skin dis-
coloration, allodynia, abnormal sweating, and impaired motor function
in the affected area. The pathogenesis of CRPS has not been deﬁnitively
determined; CRPS develops following trauma or injury in over 90% of
cases. In Japan, a 40-person case-series of peripheral sympathetic
nerve dysfunction in adolescent girls after HPV vaccination was de-
scribed; 18 of the cases were considered to have CRPS (Kinoshita
et al., 2014).More research into the possible association of HPV vaccina-
tion and CRPS is needed, and Huygen et al. used the worldwide GSK
safety database, a proprietary passive reporting system, to conduct
such research (Huygen et al., 2015).
Huygen identiﬁed 18,391 adverse event reports regarding persons
who received HPV 16/18 vaccine (Huygen et al., 2015). Of these, 17
were reports of CRPS; 5 were classiﬁed as conﬁrmed CRPS. Additional
database searcheswere conducted to assess thepossibility that differentDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.07.003.
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tional caseswere identiﬁed.Huygen concludes that evidence suggesting
an increased risk for CRPS after HPV 16/18 vaccination is lacking. The
uncertainty in Huygen's observed vs expected analysis illustrates the
challenge of using a spontaneous reporting system, inwhich the report-
ed fraction is unknown, to quantify an adverse event after immuniza-
tion (AEFI).
The voluntary, spontaneous reporting system analyzed is by its
nature incomplete. However, such systems are often used to iden-
tify “signals” of possible adverse events after vaccination. In the
United States, the Vaccine Adverse Event Reporting System
(VAERS) is a national vaccine safety monitoring system co-
administered by the U.S. Centers for Disease Control and Preven-
tion (CDC) and Food and Drug Administration (FDA). We searched
VAERS to explore how US-reported data compared to the data
used by Huygen et al.
VAERS receives spontaneous reports of AEFI from healthcare pro-
viders, manufacturers, the public, and others. Signs and symptoms of
AEFI are coded by trained personnel and entered into a database using
the Medical Dictionary for Regulatory Activities (MedDRA), a clinically
validated, internationally standardized medical terminology, which
was also used in the Huygen et al. database (Huygen et al., 2015).
VAERS data are publicly available (VAERS: Vaccine Adverse Event
Reporting System, n.a.). Between 2006 (when the ﬁrst HPV vaccine
was licensed in the United States), and July 23, 2015 when we conduct-
ed our VAERS search, VAERS had received 31,935 reports of AEFI follow-
ing HPV vaccination. Reﬂecting the approximately 1% of HPV vaccines
distributed in the U.S. that have been bivalent vaccine, approximately
1% of VAERS reports (n=215) reported receipt of bivalent HPV vaccine.
Over 67 million doses of HPV vaccine have been distributed in the
United States (Reference: Frequently Asked Questions about HPV Vaccine
Safety, US Centers for Disease Control and Prevention, March 30 2014.
http://www.cdc.gov/vaccinesafety/Vaccines/HPV/hpv_faqs.html#ﬁve.
Accessed August 20, 2015.).
We searched for US, primary reports of CRPS reported to VAERS after
receipt of any HPV vaccine (HPV2, HPV4, HPV9, and HPV of unknown
manufacturer) using the MedDRA terms, “complex regional pain syn-
drome” and “mononeuropathymultiplex”. We identiﬁed 22 (0.07%) re-
ports thatmet the search criteria for CRPS, similar to the fraction of CRPS
among reports in the GSK database (0.09%). In 21 reports, the patient
had received quadrivalent HPV vaccine; one report was for bivalentense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1015C.M. Weinbaum, M. Cano / EBioMedicine 2 (2015) 1014–1015HPV vaccine. Themedian age of persons with CRPS was 15 years (range
12–19 years); and 21 (91%) were female.
Passive reporting systems such as VAERS and GSK's have a number
of strengths, including their broad scope and timely reporting.
They can identify disproportionately reported health events after HPV
vaccination, but they have signiﬁcant limitations including over- or
under-reporting, biased reporting, and inconsistent quality and
completeness of reports. Huygen et al. found that 35% of CRPS case
reports in their database were received after the initial case in
Japan was reported in the media; increased reporting of HPV vaccine
safety concerns after media attention has been reported previously
(Eberth et al., 2014).
Such databases cannot be used to assess causality between CRPS and
receipt of HPV vaccine; such an assessment would require additional
data sources. However, CRPS cases have been reported following HPV
and other injectable vaccines, and it has been suggested that the report-
ed cases of CRPS following vaccination may simply be a result of the
minor trauma from the injection (Richards et al., 2012). Regardless of
a possible causal association between HPV vaccine and CRPS, the ﬁnd-
ings from Huygen and the data from VAERS indicate that such events
are rare.
In July 2015, the EuropeanMedicines Agency (EMA) announced that
their Pharmacovigilance Risk Assessment Committee will be reviewing
available data regarding HPV vaccines and CRPS (as well as postural or-
thostatic tachycardia syndrome) (Anon, n.a.). The EMA review will be a
welcome contribution to the scientiﬁc foundation for HPV vaccination
programs.
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